Full Paper

Intracellular bimodal nanoparticles based on quantum dots for high-field MRI at 21.1 T

  1. Jens T. Rosenberg1,2,
  2. Joshua M. Kogot3,
  3. Derek D. Lovingood3,
  4. Geoffrey F. Strouse3,
  5. Samuel C. Grant1,2,*

Article first published online: 23 JUN 2010

DOI: 10.1002/mrm.22441

Issue

Magnetic Resonance in Medicine

Magnetic Resonance in Medicine

Volume 64, Issue 3, pages 871–882, September 2010

Additional Information

How to Cite

Rosenberg, J. T., Kogot, J. M., Lovingood, D. D., Strouse, G. F. and Grant, S. C. (2010), Intracellular bimodal nanoparticles based on quantum dots for high-field MRI at 21.1 T. Magn. Reson. Med., 64: 871–882. doi: 10.1002/mrm.22441

Author Information

  1. 1

    Chemical and Biomedical Engineering, The Florida State University, Tallahassee, Florida, USA

  2. 2

    The National High Magnetic Field Laboratory, CIMAR, Tallahassee, Florida, USA

  3. 3

    Department of Chemistry and Biochemistry, The Florida State University, Dittmer Bldg, Tallahassee, Florida, USA

*The National High Magnetic Field Laboratory, 1800 E. Paul Dirac Drive, Tallahassee, FL 32310

Publication History

  1. Issue published online: 25 AUG 2010
  2. Article first published online: 23 JUN 2010
  3. Manuscript Accepted: 1 MAR 2010
  4. Manuscript Revised: 5 FEB 2010
  5. Manuscript Received: 6 OCT 2009

Funded by

  • NIH. Grant Number: NBIB R01-1E B000832

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (495K)

Keywords:

  • DOTA-Dy;
  • bimodal contrast agent;
  • high field MRI;
  • quantum dots;
  • cellular MRI

Abstract

Multimodal, biocompatible contrast agents for high magnetic field applications represent a new class of nanomaterials with significant potential for tracking of fluorescence and MR in vitro and vivo. Optimized for high-field MR applications—including biomedical imaging at 21.1 T, the highest magnetic field available for MRI—these nanoparticles capitalize on the improved performance of chelated Dy3+ with increasing magnetic field coupled to a noncytotoxic Indium Phosphide/Zinc Sulfide (InP/ZnS) quantum dot that provides fluorescence detection, MR responsiveness, and payload delivery. By surface modifying the quantum dot with a cell-penetrating peptide sequence coupled to an MR contrast agent, the bimodal nanomaterial functions as a self-transfecting high-field MR/optical contrast agent for nonspecific intracellular labeling. Fluorescent images confirm sequestration in perinuclear vesicles of labeled cells, with no apparent cytotoxicity. These techniques can be extended to impart cell selectivity or act as a delivery vehicle for genetic or pharmaceutical interventions. Magn Reson Med, 2010. © 2010 Wiley-Liss, Inc.

View Full Article (HTML) Get PDF (495K)